Results 211 to 220 of about 25,109 (253)
Some of the next articles are maybe not open access.
Cancer Research, 2023
Abstract Background: HER3 is a unique member of the EGFR family that collaborates with other EGFR receptors to induce tumorigenesis and drug resistance. Moreover, HER3 expression is linked to poor survival for patients with solid tumors.
Denis Beckford-Vera +10 more
openaire +1 more source
Abstract Background: HER3 is a unique member of the EGFR family that collaborates with other EGFR receptors to induce tumorigenesis and drug resistance. Moreover, HER3 expression is linked to poor survival for patients with solid tumors.
Denis Beckford-Vera +10 more
openaire +1 more source
Cancer Research, 2023
Abstract Background: HER3 is broadly expressed in various solid tumor types, and its expression can be upregulated by treatment with receptor tyrosine kinase inhibitors (RTKi) such as EGFR TKIs used to treat EGFR-mutated NSCLC. HER3-DXd, a novel antibody-drug conjugate (ADC) composed of a human anti-HER3 IgG1 monoclonal antibody ...
Nagiho Komatsu +4 more
openaire +1 more source
Abstract Background: HER3 is broadly expressed in various solid tumor types, and its expression can be upregulated by treatment with receptor tyrosine kinase inhibitors (RTKi) such as EGFR TKIs used to treat EGFR-mutated NSCLC. HER3-DXd, a novel antibody-drug conjugate (ADC) composed of a human anti-HER3 IgG1 monoclonal antibody ...
Nagiho Komatsu +4 more
openaire +1 more source
Abstract 3916: role of her3 v104l mutation on tumor growth and her3 stabilization
Cancer Research, 2023Abstract We aimed to determine if naturally occurring HER3 mutations could drive oncogenic activity of HER2+ HCC1569 cells in which endogenous HER3 was knocked out using CRISPR-Cas9 technology. A series of HER3 mutations found in breast cancer patients (F94L, V104L, G284R, D297Y, T355I, and E928G) were introduced via lentiviral ...
Rosalin Mishra +5 more
openaire +1 more source
HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib
Molecular Imaging and Biology, 2021Standard therapy for HER2+ breast cancers includes HER2 inhibition. While HER2 inhibitors have significantly improved therapeutic outcomes, many patients remain resistant to therapy. An important intrinsic resistance mechanism to HER2 inhibition in some breast cancers is dynamic upregulation of HER3.
Eric Wehrenberg-Klee +6 more
openaire +2 more sources
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).
Journal of Clinical Oncology, 20231004 Background: HER3-DXd is an antibody drug conjugate (ADC) comprised of a fully human anti-HER3 IgG1 monoclonal antibody (patritumab), attached to a topoisomerase 1 inhibitor via a tetrapeptide-based cleavable linker that has shown promising efficacy ...
E. Hamilton +14 more
semanticscholar +1 more source
Molecular Carcinogenesis, 2014
Various receptor tyrosine kinase (RTK) pathways were verified in many cancers including gastric cancer (GC), We sought to investigate the expression of RTKs including Her2, Her3, and Met and their transduction patterns in human GC. Over‐expression of Her2, Her3, and c‐Met in human GC was verified by immunohistochemistry leading to constitutive ...
Chen, Yun +5 more
openaire +2 more sources
Various receptor tyrosine kinase (RTK) pathways were verified in many cancers including gastric cancer (GC), We sought to investigate the expression of RTKs including Her2, Her3, and Met and their transduction patterns in human GC. Over‐expression of Her2, Her3, and c‐Met in human GC was verified by immunohistochemistry leading to constitutive ...
Chen, Yun +5 more
openaire +2 more sources
Journal of Clinical Oncology, 2022
1002 Background: Patritumab deruxtecan (HER3-DXd) is a novel, investigational ADC composed of a human anti-HER3 monoclonal antibody covalently bound to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker.
I. Krop +19 more
semanticscholar +1 more source
1002 Background: Patritumab deruxtecan (HER3-DXd) is a novel, investigational ADC composed of a human anti-HER3 monoclonal antibody covalently bound to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker.
I. Krop +19 more
semanticscholar +1 more source
Nature Cancer
Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals with breast cancer. Due to their low abundance in the circulation, robust CTC expansion protocols are urgently needed to effectively study disease progression and ...
Roberto Würth +41 more
semanticscholar +1 more source
Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals with breast cancer. Due to their low abundance in the circulation, robust CTC expansion protocols are urgently needed to effectively study disease progression and ...
Roberto Würth +41 more
semanticscholar +1 more source
Journal of Clinical Oncology, 2022
105 Background: NRG1 fusions are rare oncogenic drivers that have been identified in a variety of solid tumors. These proteins bind HER3, leading to HER2/HER3 heterodimerization and oncogenic transformation.
A. Schram +19 more
semanticscholar +1 more source
105 Background: NRG1 fusions are rare oncogenic drivers that have been identified in a variety of solid tumors. These proteins bind HER3, leading to HER2/HER3 heterodimerization and oncogenic transformation.
A. Schram +19 more
semanticscholar +1 more source
Heregulin Reverses the Oligomerization of HER3
Biochemistry, 2000We analyzed the propensity of the HER3 receptor and its extracellular domain (ECD) to undergo ligand-independent self-association. The HER3-ECD, purified from Drosophila S2 cells, binds the EGF-like domain of heregulin (hrg) with a K(d) of 1.9 nM as measured by surface plasmon resonance (SPR) studies.
R, Landgraf, D, Eisenberg
openaire +2 more sources